. . . . . "2021-12-16T19:29:24.104949"^^ . "S&T TWOC project version 2" . "2"^^ . "into the final PK / PD model, \", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells\", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" . "102"^^ . "integrated" . "[154]" . "The PK model of dopamine D(2)-like receptor ( D2DR ) antagonist sulpiride ( SUL ) as well as that of dexamethasone ( DEX ) with a time-dependent clearance" . "45"^^ . "wdxnfuun" . "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." . "wdxnfuun-TRIPLE-ABSTRACT-10" . "efficacy" . "d2dr" . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB" . "YIdvx24rWgXLCthCI6kquLL8kdpkWYX28O0OBG0U3Sv7ozm1dOlbq0ho8doXzApsdRn7h1lXo/1wP7myvcWULrFdusHrSpyByZZofa+gqAzg5cqBtuaggzSqclapBzdpFRLoiH6jAcnaiZj2NSP8ZoBRGv83BpBBtmxCq4sK9Gw=" . . "2021-12-16T19:29:24.104949"^^ . .